Biomedical Engineering Reference
In-Depth Information
34. Hoshi A. Castaner J. TAS-103: antineoplastic topoisomerase I and II inhibitor. Drugs
Future 1998;23:513-515.
35. Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, Yamada Y.
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on
topoisomerases I and II. Jpn. J. Cancer Res. 1997;88:992-1002.
36. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern
MR, Tan KB, Johnson RK. Camptothecin hyper-resistant P388 cells: drug-dependent
reduction in topoisomerase I content. Oncol. Res. 1992;4(11-12):481-488.
37. Long BH, Wang L, Lorico A, Wang RC, Brattain MG, Casazza AM. Mechanisms of
resistance to etoposide and teniposide in acquired resistant human colon and lung
carcinoma cell lines. Cancer Res. 1991;51(19):5275-5283.
38. Cory AH, Owen TC, Barltrop JA, Cory, JG. Use of an aqueous soluble tetrazolium/
formazan assay for cell growth assays in culture. Cancer Commun. 1991;3:207-212.
39. Long BH, Bifano M, Stadnick LK, Fairchild CR, Cornell LC, Raventos-Suarez C,
Menendez AT. Cytotoxic mechanism of TAS-103 is related to topoisomerase II
mediated DNA cleavage. 91st Annual Meeting, Proceedings of the American
Association for Cancer Research, Mar 24-28, 2000; Proc. Am. Assoc. Cancer Res.
2000;41:819.
40. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug
resistance (MDR). Semin. Oncol. 2005;32 (6 Suppl. 7): S3-S8.
41. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli
E, Ranelletti FO, Ferrandina G, Scambia G. Class III beta-tubulin overexpression is a
prominent mechanismof paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res.
2005;11(1):298-305.
42. Hunt JT. Discovery of ixabepilone. Mol. Cancer Ther. 2009;8(2):275-281.
43. Lee, FYF, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD,
Rose WC, Kramer RA. BMS-247550: a novel epothilone analog with a mode of action
similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res.
2001;7:1429-1437. (Note: This paper was published with a typo in the spelling of one
name: Reventos instead of Raventos.)
44. Lee FYF, Wen ML, Shen H, She Y, Lenhart R, Covello K, McGlinchey K, Menard K,
Wiebeiek A, Raventos-Suarez C, Gan J, Platero S, Kramer R. Ixabepilone overcomes
multiple mechanisms of drug resistance including overexpression of class III B tubulin and
breast cancer resistance protein. 6th European Breast Cancer Conference (EBCC), Berlin,
Germany, April 2008.
45. Hunt JT, Ding CZ, Batorsky R, Bednarz M, Bhide R, Cho Y, Chong S, Chao S, Gullo-
Brown J, Guo P, Kim SH, Lee FY, Leftheris K, Miller A, Mitt T, Patel M, Penhallow BA,
Ricca C, Rose WC, Schmidt R, Slusarchyk WA, Vite G, Manne V. Discovery of (R)-7-
cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-
1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent
preclinical antitumor activity. J. Med. Chem. 2000;43(20):3587-3595.
46. Rose WC, Lee FY, Fairchild CR, Lynch M, Monticello T, Kramer RA, Manne V.
Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel
farnesyltransferase inhibitor. Cancer Res. 2001;61(20):7507-7517.
47. Raventos-Suarez C, Class K, Lee F. The pro-apoptotic FT-inhibitor BMS-214662
selectively targets non-proliferating tumor cells. Demonstration by a new flow
Search WWH ::
Custom Search